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ABSTRACT
Interferon (IFN)-regulatory factor 5 (IRF-5) is a transcription factor that induces inflammatory responses after engagement and
signaling by pattern recognition receptors. To define the role of IRF-5 during bunyavirus infection, we evaluated Oropouche
virus (OROV) and La Crosse virus (LACV) pathogenesis and immune responses in primary cells and in mice with gene deletions
in Irf3, Irf5, and Irf7 or in Irf5 alone. Deletion of Irf3, Irf5, and Irf7 together resulted in uncontrolled viral replication in the liver
and spleen, hypercytokinemia, extensive liver injury, and an early-death phenotype. Remarkably, deletion of Irf5 alone resulted
in meningoencephalitis and death on amore protracted timeline, 1 to 2 weeks after initial OROV or LACV infection. The clinical
signs in OROV-infected Irf5/mice were associated with abundant viral antigen and terminal deoxynucleotidyltransferase-
mediated dUTP-biotin nick end labeling (TUNEL)-positive cells in several regions of the brain. Circulating dendritic cell (DC)
subsets in Irf5/mice had higher levels of OROV RNA in vivo yet produced lower levels of type I IFN than wild-type (WT) cells.
This result was supported by data obtained in vitro, since a deficiency of IRF-5 resulted in enhanced OROV infection and dimin-
ished type I IFN production in bone marrow-derived DCs. Collectively, these results indicate a key role for IRF-5 in modulating
the host antiviral response in peripheral organs that controls bunyavirus neuroinvasion in mice.
IMPORTANCE
Oropouche virus (OROV) and La Crosse virus (LACV) are orthobunyaviruses that are transmitted by insects and cause meningi-
tis and encephalitis in subsets of individuals in the Americas. Recently, we demonstrated that components of the type I inter-
feron (IFN) induction pathway, particularly the regulatory transcription factors IRF-3 and IRF-7, have key protective roles dur-
ing OROV infection. However, the lethality in Irf3/ Irf7/ (DKO)mice infected with OROVwas not as rapid or complete as
observed in Ifnar/mice, indicating that other transcriptional factors associated with an IFN response contribute to antiviral
immunity against OROV. Here, we evaluated bunyavirus replication, tissue tropism, and cytokine production in primary cells
andmice lacking IRF-5. We demonstrate an important role for IRF-5 in preventing neuroinvasion and the ensuing encephalitis
caused by OROV and LACV.
The interferon (IFN)-regulatory factor (IRF) family of tran-scription factors has a central role in regulating innate im-
mune cell development and responses (1). Several IRF family
members (e.g., IRF-1, IRF-3, IRF-5, and IRF-7) are present in the
cytoplasm in an inactive form and then phosphorylated after pat-
tern recognition receptor engagement and signaling. These events
facilitate nuclear translocation, binding to DNA promoter ele-
ments, and induction of antiviral and proinflammatory genes that
modulate immunity (2). Canonical IFN induction pathways that
are regulated by Toll-like receptors (TLRs) and RIG-I-like recep-
tors (RLRs) converge on activation of IRF-3 and IRF-7 (3).
IRF-5 acts downstream of the TLR-MyD88 and RLR-MAVS
signaling pathways, via a TRAF6- and IRAK1-dependent mecha-
nism, to induce expression of proinflammatory cytokines, includ-
ing interleukin-6 (IL-6), IL-12, and TNF- (4). IRF-5 is expressed
constitutively in several hematopoietic cells, including B cells,
monocytes, macrophages (M), and dendritic cell (DC) subsets
(5, 6). IRF-5 regulates differentiation of lymphoid cells and innate
immune responses but also is implicated in oncogenesis and
apoptosis (7, 8). During B cell development, IRF-5 regulates ex-
pression of Blimp-1, a protein required for the formation of im-
munoglobulin-secreting plasma cells. As a consequence, Irf5/
mice have increased numbers of CD19 B220 cells and reduced
plasma cell expansion and isotype switching in response to anti-
gens or pathogens (9–11). A deficiency of IRF-5 also resulted in
reduced IFN-, IFN-, and IL-6 production by TLR-7- and TLR-
9-stimulated DCs or IL-6 production by B cells (9, 12), and this
was associated with resistance to shock syndrome induced by un-
methylated CpG DNA and lipopolysaccharide (LPS) (4). Irf5 al-
leles with enhanced promoter activity are linked to autoimmune
disorders in humans, including systemic lupus erythematosus,
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rheumatoid arthritis, Sjögren’s syndrome, multiple sclerosis, and
inflammatory bowel disease (13–16).
Recent studies have illustrated the importance of IRF-5 func-
tion in antiviral immunity (17). After MAVS signaling, IRF-5 acts
coordinately with IRF-3 and IRF-7 to regulate type I IFN re-
sponses in myeloid DCs after West Nile virus (WNV) infection
(18). In addition, IRF-5 shapes the early innate immune response
against WNV in the draining lymph node (11). An IRF-5 defi-
ciency was associated with lower levels of proinflammatory cyto-
kines, chemokines, and activated immune cells in lymphoid tis-
sues within 2 days of WNV infection (11). Irf5/mice also had a
mildly bluntedWNV-specific antibody response, with fewer anti-
gen-specific memory B cells and long-lived plasma cells (11).
Oropouche virus (OROV) is an arthropod-transmitted, envel-
oped, negative-sense orthobunyavirus of the family Bunyaviridae
that has caused periodic outbreaks of a debilitating febrile illness
in South America (19). Oropouche fever is the second most fre-
quent arthropod-transmitted viral disease in Brazil, and more than
500,000caseshavebeenconfirmed inBrazil,Peru,Trinidad,Panama,
and Suriname (19–21). OROV infection can progress to meningitis
and/or encephalitis in some patients (22–24). Despite its clinical im-
portance, little is known about the factors that determineOROVdis-
semination into the central nervous system (CNS).
A recent study in mice with targeted gene deletions provided
insight into mechanisms of innate immune restriction of OROV
infection (25). The host type I IFN antiviral response is essential
for controllingOROV infection, asmice lacking IFN-/ receptor
(Ifnar/) or signaling molecules and transcription factors in-
volved in IFN production (e.g.,Mavs/, Irf3/, or Irf7/) sus-
tained high levels of virus replication in the liver and spleen (25).
However, Irf3/ Irf7/ double-knockout (DKO)mice were not
as vulnerable to OROV or La Crosse virus (LACV) (a second or-
thobunyavirus) infection as were Ifnar/ mice (25), suggesting
that additional transcriptional factors regulated IFN-dependent
antiviral immunity.
To define the role of IRF-5 in restricting OROV infection, we
infected Irf5/, Irf3/ Irf7/ DKO, or Irf3/ Irf5/ Irf7/
triple-knockout (TKO)mice with OROV.Whereas the combined
loss of Irf3 and Irf7 or Irf3, Irf5, and Irf7 expression resulted in
rapid systemic disease with high lethality rates and extensive virus
replication in the liver, the deletion of Irf5 alone yielded a distinct
phenotype. OROV infection in Irf5/mice was associated with a
protracted disease that recapitulated features of human infection,
with signs of neurological involvement and high levels of virus
accumulating in the brain and spinal cord.
MATERIALS AND METHODS
Ethics statement. This study was carried out in accordance with the rec-
ommendations in theGuide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The protocols were approved by the
Institutional Animal Care andUseCommittee at theWashingtonUniver-
sity School of Medicine (Assurance no. A3381-01). Inoculations were
performed under anesthesia that was induced and maintained with
ketamine hydrochloride and xylazine, and all efforts were made to mini-
mize animal suffering.
Viruses.OROV (strain BeAn 19991) and LACV (original strain) were
provided by E. Arruda (São Paulo University, Ribeirão Preto, Brazil) and
A. Pekosz (JohnsHopkinsUniversity, Baltimore,MD,USA), respectively.
OROVand LACV stocks were produced inVero cells. Studies withOROV
were conducted under enhanced biosafety level 3 (BSL3) and animal BSL3
(A-BSL3) containment at Washington University School of Medicine
with appropriate personal protective equipment (respirators) and ap-
proval from theU.S. Department of Agriculture. Experiments with LACV
were performed under BSL2 and A-BSL2 conditions.
Mouse experiments.Wild-type (WT) C57BL/6 mice were purchased
from Jackson Laboratories. Congenic Ifnar/, Irf5/, Irf3/ Irf7/
DKO, and Irf3/ Irf5/ Irf7/ TKO mice have been described previ-
ously (4, 18, 26, 27). Irf5/ mice were the gift of T. Taniguchi (Tokyo,
Japan), obtained from I. Rifkin (Boston, MA), and had been backcrossed
for eight generations. After detection of a homozygousDock2mutation in
this line, we backcrossed Irf5/mice for five additional generations and
selected animals that were Dock2wt/wt using PCR-based genotyping (11).
All mice were bred in a specific-pathogen-free facility atWashingtonUni-
versity. Subcutaneous inoculations were performed by injection in the foot-
padwith 106 focus-forming units (FFU) ofOROVand105 FFUof LACV in a
volume of 50 l. Intracranial injections were performed with 102 FFU of
OROV in a volume of 10l. Infection experiments were designed with 5- to
6-week-old mice and 8-week-old mice for OROV and LACV, respectively.
The 8-week-oldmice were usedwith LACVbecause youngerWTmice had a
highermortality rate,which limitedour ability todetect differences in theKO
mice. Survival and weight loss were monitored for 21 days.
Measurement of viral burden.OROV-infectedmice were euthanized
at days 4, 6, 9, and 12 postinfection. LACV-infectedmice were euthanized
at days 4, 8, and 12 postinfection. Animals were perfused extensively with
20ml of phosphate-buffered saline (PBS) at the time of euthanasia. Liver,
spleen, kidney, lung, heart, brain, and spinal cord were harvested,
weighed, and homogenized with zirconia beads in MagNA Lyser instru-
ment (Roche Life Science) in 1 ml of minimal essential medium (MEM)
supplemented with 2% heat-inactivated fetal bovine serum (FBS). All
homogenized tissues and approximately 200 l of serum from infected
animals were stored at80°C until virus titration.
Viral burden was determined by focus-forming assay on Vero cells.
Samples were thawed, clarified by centrifugation (2,000 g at 4°C for 10
min), and then diluted serially prior to infection of Vero cells in 96-well
plates. Infected-cell foci were detected 22 to 24 h later, following overnight
fixation with 1% paraformaldehyde and incubation with a 1:1,000 dilu-
tion of polyclonal mouse anti-OROV ascites fluid (ATCC, VR1228AF) or
a 1:100 dilution of hybridoma cell supernatants containing the anti-LACV
monoclonal antibodies (MAbs) 807-31 and 807-33 (provided by A.
Pekosz), all in a volume of 50 l for 2 h at room temperature. After
incubation for 1 h with 50 l of a 1:2,000 dilution of horseradish peroxi-
dase (HRP)-conjugated goat anti-mouse IgG (Sigma), foci were detected
by addition of TrueBlue detection reagent (KPL). The spots were analyzed
with a CTL Immunospot instrument.
Measurement of viral RNA. Tissue samples from WT and Irf5/
mice were extracted with the RNeasy kit (Qiagen). OROV RNA levels in
serum, liver, spleen, lung, kidney, brain, and spinal cord were determined
by TaqMan one-step quantitative reverse transcriptase PCR (qRT-PCR)
and expressed on a log10 scale as viral RNA equivalents per gram or per
milliliter after comparison with a standard curve produced using serial
10-fold dilutions of OROV RNA. The amplification of the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene (IdT catalog no.
Mm.PT.39a.1) was used as a control for normalization. All reactions were
performed using 300 ng of RNA, 2.5l of 10 PrimeTime solution (IdT)
(OROV-F, 5=-TACCCAGATGCGATCACCAA-3=; OROV-R, 5=-TTGCG
TCACCATCATTCCAA-3=; OROV-Probe, 5=-/56-FAM/TGCCTTTGGC
TGAGGTAAAGGGCTG/36-TAMSp/-3=), 12.5l of TaqManmastermix
(Applied Biosystems), and 0.625l of reverse transcriptase (Applied Bio-
systems) in a final volume of 25l. The cycling algorithmwas 48°C for 30
min, 95°C for 10 min, and 45 cycles of 95°C for 15 s and 60°C for 1 min.
Blood chemistry analysis. Serum fromWT, Irf5/, or TKOmicewas
isolated on days 4, 6, 9, and 12 after OROV infection. Chemistry analyses
were performed using a Catalyst Dx Chemistry Analyzer (IDEX Labora-
tories) after treatment with -propiolactone (BPL) (Sigma) for 30 min at
37°C to inactivate infectious virus. Treatment with BPL did not impact
chemistry results.
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Cytokine bioplex assay. At days 4, 6, 9, and 12 after OROV infection
of WT, Irf5/, and TKO mice, serum was collected and cytokine levels
were measured using the Bioplex Pro mouse cytokine assay (Bio-Rad).
The levels of the following cytokines and chemokines were determined:
IL-1, IL-1, IL-2, IL-3, IL-4, IL-6, IL-9, IL-10, IL-12p40, IL-12p70,
IL-13, IL-17, eotaxin (CCL11), granulocyte colony-stimulating factor (G-
CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF),
IFN-	, KC (CXCL1), monocyte chemoattractant protein 1 (MCP-1)
(CCL-2), MIP-1 (CCL3), MIP-1 (CCL4), RANTES (CCL5), and
TNF-.
Quantification of type I IFNactivity.Levels of type I IFN in the sera of
WT and Irf5/mice at 1, 2, or 3 days after OROVwere determined by an
encephalomyocarditis virus cytopathic effect bioassay in L929 cells as de-
scribed previously (28). Briefly, all samples were treatedwith citrate buffer
(40 mM citric acid, 10 mM KCl, 135 mMNaCl [pH 3.0]) for 10 min and
neutralizedwithminimal essentialmediumbufferedwith 45mMHEPES,
pH 8.0. The amount of type I IFN per milliliter of serum was calculated
and compared to a standard curve using recombinant IFN- (PBL Assay
Science).
Histology, TUNEL staining, and immunohistochemistry. Liver and
spleen tissues were obtained from WT, Irf5/, and TKO mice at day 4
after OROV infection. Brain tissue from WT and Irf5/ KO mice was
harvested at day 12 after virus inoculation. All samples were fixed in 4%
paraformaldehyde (in PBS) for 24 h at 4°C, dehydrated in increasing
ethanol concentrations, and embedded in paraffin. Hematoxylin-eosin
staining of paraffin-embedded tissues was performed by the Digestive
Diseases Research Core CenterMorphology Core ofWashington Univer-
sity. Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL) staining from liver and spleen sections was per-
formed using an in situ cell death detection kit, peroxidase (POD)
(Roche), as described by the manufacturer. TUNEL staining of brain sec-
tions was performed after permeabilization with proteinase K (Roche) for
30 min using the cell death detection kit, tetramethylrhodamine (TMR)
red (Roche), followed by counterstaining with DAPI (4=,6=-diamidino-2-
phenylindole) (Invitrogen) for 5min. As a positive control, tissue sections
were treatedwithDNase (Sigma) for 10min to introduce nicks intoDNA.
Slides were visualized using an Axioskop (Zeiss) microscope, and images
were captured using AxioCam HRm (Zeiss) and AxioVision Rel4.8
(Zeiss) software.
For OROV antigen detection, tissues sections were deparaffinized, re-
hydrated, and treated with citrate buffer (pH 6.0) for antigen retrieval.
Endogenous peroxidases were quenched by incubation with 4%H2O2 for
30 min, and the antigen detection was performed using the “Mouse on
Mouse” (MOM) immunodetection kit according to the manufacturer’s
protocol (Vector Laboratories). All sections were incubated with an avi-
din-biotin blocking solution and MOM mouse immunoglobulin-block-
ing reagent for 15 min at room temperature and then incubated with
mouse polyclonal anti-OROV ascites fluid (1:100) for 2 h at room tem-
perature. Sections were then incubated with a MOM biotinylated anti-
mouse IgG antibody for 1 h and with a streptavidin-peroxidase Ultrasen-
sitive Polimer (Sigma) for 15 min at room temperature. Antigen-positive
cells were visualized atmagnifications of20 and40 in aZeiss Axioskop
microscope, and images were captured using an AxioCam MRC digital
color camera after incubation with 3,3=-diaminobenzidine (DAB)-HRP
substrate (Vector) and counterstaining with hematoxylin.
FIG 1 Irf3/ Irf5/ Irf7/ TKO mice are vulnerable to OROV infection, whereas deletion of IRF-5 alone induces a disease with a protracted course. (A)
Survival analysis of 6-week-old mice after inoculation with 106 PFU of OROV by subcutaneous inoculation in the footpad. WT (n 
 33), Ifnar/ (n 
 25),
Irf5/ (n
 33), Irf3/ Irf7/ DKO (n
 39), and Irf3/ Irf5/ Irf7/ TKO (n
 17) mice were used. Data are pooled from at least three independent
experiments. Asterisks indicate differences that were statistically significantwith a comparison toWTmice by the log rank test (****,P 0.0001). (B to F)Weight
loss of infected (dead or surviving animals considered separately) and noninfectedWT (n
 33 and n
 10 for infected and noninfected mice, respectively) (B),
Ifnar/ (n
 25 infected and n
 3 noninfected) (C), Irf5/ (n
 20 dead, n
 13 survivors, and n
 4 noninfected) (D), Irf3/ Irf7/DKO (n
 19 dead,
n 
 20 survivors, and n 
 13 noninfected) (E), and Irf3/ Irf5/ Irf7/ TKO (n 
 17 infected, n 
 3 noninfected) (F) mice. The weight loss curves were
compared using 2-way ANOVA. Asterisks indicate differences that were statistically significant with a comparison to noninfectedmice (*, P 0.05; **, P 0.01;
***, P 0.001).
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FIG 2 Viral burden inmice infected with OROV. (A toH) Viral burden after OROV infection ofWT, Irf5/, Irf3/ Irf7/DKO, and Irf3/ Irf5/ Irf7/
TKOmice wasmeasured by focus-forming assay in samples from serum (A), liver (B), spleen (C), kidney (D), lung (E), heart (F), brain (G), and spinal cord (H).
(I toO)Viral burden afterOROV infection ofWT and Irf5/micewas determined by qRT-PCR in samples from serum (I), liver (J), spleen (K), kidney (L), lung
(M), brain (N), and spinal cord (O). Data points represent individual mice. Bars indicate median values and were obtained from 6 to 15 mice per time point.
Dashed lines represent the limit of sensitivity of the assay. Asterisks indicate statistical significance as judged by theMann-Whitney test with a comparison toWT
mice (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001). A blue cross indicates that all OROV-infected TKO animals were dead at the indicated time
point. The viral burden data from Irf3/ Irf7/ DKO mice at days 4 and 6 after OROV infection were published previously (25) and are provided as a
comparison to the Irf3/ Irf5/ Irf7/ TKO mice.
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OROV replication in primary cells. Macrophage (M) and DC cul-
tures were derived from bone marrow isolated from WT, Irf5/, and
TKO mice and cultured for 7 days in medium supplemented with 40
ng/ml M-CSF (PeproTech) or 20 ng/ml of both GM-CSF and IL-4 (Pep-
roTech), respectively. Multistep virus growth curves were determined us-
ing a multiplicity of infection (MOI) of 0.001. The viral titer in the cell-
free supernatant was determined by FFU assay on Vero cells at the
following time points after infection: 0, 1, 4, 12, 24, 36, 48, and 60 h.
Isolation ofOROV-infected cells.Whole bloodwas collected in tubes
containing EDTA. Erythrocytes were removed after 10 min of incubation
in red blood cell lysis solution buffer (Miltenyi Biotech). Nonspecific an-
tibody binding was inhibited after incubation with Fc block (BD Biosci-
ence) for 15min. Cell suspensions from six differentWTand Irf5/mice
were purified sequentially by positive selection with CD19, CD3, and
CD11bmicrobeads (Miltenyi Biotech), following themanufacturer’s pro-
tocol. A separate experiment was conducted to purify plasmacytoid DC
(pDCs) using B220 orCD11cmicrobeads (Miltenyi Biotech). All cell pop-
ulations were tested by qRT-PCR for OROV and Gapdh RNA levels and
analyzed in parallel by flow cytometry by staining with antibodies to CD3,
CD19, CD11b, and CD11c.
Quantification of Ifna and Ifnb RNAs. The levels of Ifna and Ifnb
mRNAs were determined by qRT-PCR in DCs,M, and sorted cells from
WT and Irf5/ mice, following previously published procedures (25).
Briefly, RNA from target cells was extracted using the RNeasy kit (Qiagen)
and treated with Turbo DNase (Life Technologies) for 2 h at 37°C. qRT-
PCRwas performed by one-step reaction with previously described prim-
ers andprobes (25). All reactionswere assembled in a final volumeof 25l
with 300 ng of RNA, 1 PrimeTimemix (IntegratedDNATechnologies),
and 12.5 l of TaqMan master mix (Applied Biosystems) by using the
cycling algorithm described above. All reactions were normalized to
Gapdh RNA using previously published primers and probe (25), and re-
sults were expressed on a log2 scale as fold increase overmock according to
the threshold cycle (CT) method (29).
Quantitation of antibodies. The titer of neutralizing antibodies was
determined on serum obtained at days 8 and 12 after OROV infection of
WT and Irf5/mice by a standard plaque reduction neutralization assay
(30). Plaques were scored visually after incubation with serial dilutions of
the mice serum, and the 50% plaque reduction neutralization titer
(PRNT50) was determined.
Data analysis. All data were analyzed with Prism software (GraphPad
Software). Kaplan-Meier survival curves were analyzed by the log rank
test, and weight losses were compared using 2-way analysis of variance
(ANOVA). For viral burden analysis, the log titers were analyzed by the
Mann-Whitney test. qRT-PCR results also were compared using 2-way
ANOVA. A P value of0.05 indicated statistically significant differences.
TABLE 1 Blood urea nitrogen, alkaline phosphatase, and creatine kinase levels after OROV infectiona
Test Genotype
4 dpi 6 dpi 9 dpi 12 dpi
Value P Value P Value P Value P
BUNb WT 22.5 3.02 22.0 3.4 19.0 2.42 19.5 3.88
Irf5/ 19.5 7.27 0.10 14.0 3.5 0.07 17.0 3.3 0.34 21.5 6.8 0.99
TKO 19.0 5.5 0.25 Dead Dead Dead
ALKPc WT 144 34.6 161 41.0 177 10.9 126 30.3
Irf5/ 125 31.3 0.26 134 25.7 0.27 123 21.6 0.09 151 64.4 0.71
TKO 103 56.8 0.14 Dead Dead Dead
CKd WT 5066 1761 6657 888 379.5 171 551 161
Irf5/ 6215 585 0.46 6666 999 0.26 3088 820 0.05 3133 998 0.05
TKO 6478 1315 0.92 Dead Dead Dead
a WT, Irf5/ or Irf3/ Irf5/ Irf7/ (TKO) mice were inoculated with OROV. Serum was collected at 4, 6, 9, and 12 days postinfection (dpi), and blood chemistry was
measured by a Catalyst Dx Chemistry Analyzer. Data represent the mean standard deviation for 5 to 11 mice per group. Statistical significance was determined using the Mann-
Whitney test, and P values were obtained after comparison to WT mice infected in parallel.
b BUN was quantified in mg/dl.
c ALKP was quantified in U/liter.
d CK was quantified in U/liter.
FIG 3 Blood chemistry reveals liver injury after OROV infection in Irf5/ and Irf3/ Irf5/ Irf7/ TKO mice. Alanine aminotransferase (ALT) (A),
aspartate aminotransferase (AST) (B), and glucose (GLU) (C) levels were measured from serum samples of WT, Irf5/ and Irf3/ Irf5/ Irf7/ TKOmice
(n
 4 to 13 for each group) obtained 4, 6, 9, and 12 days after infection with 106 FFU of OROV. Data points represent individual mice and were pooled from
two independent experiments. Asterisks indicate statistical significance with a comparison to WT mice as judged by the Mann-Whitney test (*, P 0.05;
**, P  0.01; ***, P  0.001; ****, P  0.0001). Dashed lines represent the mean values obtained from three mock-infected animals.
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TABLE 2 Serum cytokine and chemokine levels after OROV infectiona
Cytokine Genotype
4 dpi 6 dpi 9 dpi 12 dpi
pg/ml P pg/ml P pg/ml P pg/ml P
IL-1 WT 1.0 1.58 3.6 2.3 1.2 2.1 0.8 1.8
Irf5/ 2.5 4.3 056 2.5 7.9 0.84 3.4 4.1 0.69 2.1 5.1 0.51
TKO 0.0 12.8 0.57 Dead Dead Dead
IL-1 WT 199 44 200 53 192 24 180 18
Irf5/ 260 156 0.22 145 294 0.71 188 74 0.89 225 123 0.64
TKO 175 138 0.53 Dead Dead Dead
IL-2 WT 18.3 14.6 17.5 21.9 16.7 11.4 17.8 9.0
Irf5/ 50.1 39.1 0.32 43.1 77.3 0.26 22.8 11.5 0.78 11.5 11.2 0.41
TKO 7.0 19.3 0.02 Dead Dead Dead
IL-3 WT 7.5 11.9 16.4 13.2 21.5 6.1 26.1 8.9
Irf5/ 7.8 4.3 0.50 6.9 7.1 0.29 39.9 21.8 0.38 36.2 19.2 0.52
TKO 6.9 19.2 0.82 Dead Dead Dead
IL-4 WT 0.0 8.3 7.5 9.0 14.2 5.8 15.9 6.5
Irf5/ 0.0 4.8 0.42 0.0 2.6 0.17 24.0 12.6 0.29 22.7 11.3 0.45
TKO 0.0 1.3 0.41 Dead Dead Dead
IL-5 WT 15.0 7.5 17.4 7.1 22.9 5.1 21.6 4.9
Irf5/ 20.0 10.0 0.75 19.2 19.8 0.76 25.3 13.1 0.41 11.3 10.5 0.62
TKO 8.7 4.3 0.06 Dead Dead Dead
IL-6 WT 4.5 1.5 5.0 2.9 4.2 0.9 4.7 1.3
Irf5/ 8.9 6.0 0.17 4.5 7.8 0.55 6.9 2.9 0.07 6.1 3.9 0.9
TKO 100 301 0.0001 Dead Dead Dead
IL-9 WT 117 115 68 131 0.0 7.9 0.0 16.9
Irf5/ 213 237 0.35 0.0 143 0.49 0.0 0.0 0.99 0.0 0.0 0.99
TKO 0.0 96 0.24 Dead Dead Dead
IL-10 WT 20.8 16.3 24.5 14.4 20.1 11.7 21.7 7.0
Irf5/ 53.5 27.7 0.17 57.0 44.6 0.30 34.3 17.6 0.78 28.1 16.9 0.9
TKO 10.0 27.9 0.58 Dead Dead Dead
IL-12 (p40) WT 29.3 30.9 29.8 17.6 19.5 1.5 22.2 7.5
Irf5/ 27.8 5.9 0.51 32.0 16.5 0.71 31.0 11.5 0.06 22.6 10.0 0.87
TKO 191 125 0.0001 Dead Dead Dead
IL-12 (p70) WT 23.9 12.2 24.8 8.8 22.8 2.2 23.6 4.3
Irf5/ 33.8 17.9 0.23 26.8 25.6 0.85 53.6 28.5 0.38 49.5 27.5 0.64
TKO 22.6 13.9 0.98 Dead Dead Dead
IL-13 WT 28.8 26.2 45.8 52.1 26.5 38.2 35.4 11.5
Irf5/ 89.8 281.4 0.054 216 330 0.19 25.2 23.8 0.66 11.5 26.4 0.62
TKO 13.4 62.0 0.30 Dead Dead Dead
IL-17 WT 5.6 5.1 8.7 6.6 12.8 3.2 13.2 4.1
Irf5/ 7.6 4.0 0.87 5.8 5.4 0.53 23.1 14.8 0.37 20.4 11.8 0.64
TKO 7.5 5.3 0.91 Dead Dead Dead
Eotaxin WT 455 287 502 230 513 135 454 221
Irf5/ 527 413 0.87 512 796 0.94 559 517 0.89 281 490 0.62
TKO 30.9 221 0.02 Dead Dead Dead
G-CSF WT 15.9 5.2 14.8 5.5 15.0 1.8 18.1 4.2
Irf5/ 15.9 30.0 0.94 9.6 13.6 0.47 29.9 22.5 0.38 19.3 14.0 0.77
TKO 1499 2899 0.0001 Dead Dead Dead
(Continued on following page)
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RESULTS
Irf3/ Irf5/ Irf7/ TKO mice are highly vulnerable to
OROV infection. Because the lethality in Irf3/ Irf7/ DKO
mice after OROV infection was not as rapid or complete as that
observed in Ifnar/ mice (25) (Fig. 1A, C, and E), we hypothe-
sized that other transcription factors implicated in the induction
of antiviral immunity restricted OROV pathogenesis. Accord-
ingly, we evaluated OROV pathogenesis in 5- to 6-week-old
Irf3/ Irf5/ Irf7/ TKO mice after injection with 106 FFU of
OROV by a subcutaneous route. Analogous to results with If-
nar/ mice, OROV infection of TKO mice caused rapid weight
loss and resulted in 100%mortality, with a mean of survival time
of 4 days (Fig. 1A, C, and F). OROV-infected Irf3/ Irf5/
Irf7/ TKOmice exhibited lethargy and decreased body temper-
ature, especially at day 4 after infection, but did not show signs
of neuroinvasive disease, such as ataxia, seizures, tremors, or
paralysis.
Vulnerability of Irf5/ mice to OROV infection. To assess
the role of IRF-5 in restricting OROV infection more directly, we
inoculated 5- to 6-week-old Irf5/ and congenic wild-type (WT)
mice with OROV. Whereas 39% of Irf5/ mice succumbed to
OROV infection,WTmice had nomortality or signs of morbidity
(Fig. 1A and B). Irf5/ mice exhibited a protracted course of
OROV disease compared to Irf3/ Irf5/ Irf7/ TKO mice,
with signs of neurological involvement and lethality starting at
days 7 and 9 after infection, respectively (Fig. 1A, D, and F). Al-
most 50% of Irf5/ OROV-infected mice developed signs of se-
vere disease after day 7, including lethargy, shivering, ataxia, limb
paralysis, dyskinesia, hypothermia, and weight loss.
Viral burden studies. To determine the basis for their suscep-
tibility to OROV infection, we inoculated WT, Irf5/, Irf3/
Irf7/ DKO, and Irf3/ Irf5/ Irf7/ TKO mice and mea-
sured viral burdens in the serum, liver, spleen, kidney, lung, heart,
brain, and spinal cord at days 4, 6, 9, and 12 after infection. As
reported previously, infectious OROV was not recovered from
any site in WT mice at any of the days analyzed (25). In compar-
ison, all Irf3/ Irf5/ Irf7/ TKO mice developed viremia
(3.4103 to1.3108FFU/ml), and infectiousOROVwasrecovered
from the liver (4.2 106 to 1.3 109 FFU/g) and spleen (5.2 106
to 1.9 1010 FFU/g) at day 4 after infection (Fig. 2A to C). Infec-
tiousOROValsowas present in the kidneys (5.2 103 to 5.9 107
FFU/g) and lungs (1.3 103 to 4.8 107 FFU/g) of approximately
50%of Irf3/ Irf5/ Irf7/TKOmice onday 4 (Fig. 2D andE).
However, OROV was not recovered from heart, brain, or spinal
cord of Irf3/ Irf5/ Irf7/ TKO mice at this time point (Fig.
2F to H). The levels of OROV in the sera, livers, and spleens of
TABLE 2 (Continued)
Cytokine Genotype
4 dpi 6 dpi 9 dpi 12 dpi
pg/ml P pg/ml P pg/ml P pg/ml P
GM-CSF WT 64.4 26.6 75.9 29.3 94.9 15.7 93.8 24.0
Irf5/ 60.6 37.9 0.47 35.5 61.3 0.34 109.9 66.4 0.77 106.8 62 0.64
TKO 39.8 30.3 0.16 Dead Dead Dead
IFN-	 WT 2.1 2.1 2.4 1.4 1.9 0.5 1.6 0.7
Irf5/ 4.7 2.7 0.34 3.4 7.5 0.76 2.1 0.8 0.29 1.6 1.8 0.9
TKO 2.1 3.1 0.97 Dead Dead Dead
KC WT 30.0 9.6 31.1 19.7 23.0 2.8 27.3 7.8
Irf5/ 24.4 42 0.87 24.3 14.5 0.24 37.7 20.8 0.07 19.8 9.3 0.87
TKO 151 465 0.0001 Dead Dead Dead
MCP-1 WT 226 113 237 132 252 59 222 61
Irf5/ 252 141 0.42 279 235 0.59 300 219 0.99 134 230 0.62
TKO 146 273 0.92 Dead Dead Dead
MIP-1 WT 1.8 1.4 2.2 1.8 2.6 1.3 2.8 1.4
Irf5/ 0.5 0.7 0.18 2.4 6.4 0.84 4.7 2.6 0.3 3.2 2.2 0.92
TKO 13.1 9.7 0.0016 Dead Dead Dead
MIP-1 WT 38.5 22.4 47.7 20.4 53.1 6.6 55.0 10.0
Irf5/ 34.0 20.1 0.51 44.6 29.7 0.79 71.0 40.2 0.36 76.9 38.7 0.62
TKO 14.4 10.6 0.02 Dead Dead Dead
RANTES WT 15.1 5.8 14.9 5.1 14.5 1.2 16.1 2.3
Irf5/ 16.7 1.7 0.27 16.6 18.2 0.76 29.7 16.0 0.38 25.8 14.3 0.64
TKO 20.3 15.1 0.01 Dead Dead Dead
TNF- WT 271 193 370 182 425 65 451 111
Irf5/ 358 198 0.97 230 307 0.47 621 354 0.38 596 347 0.64
TKO 130 302 0.36 Dead Dead Dead
a WT, Irf5/ or Irf3/ Irf5/ Irf7/ (TKO) mice were inoculated with OROV. Serum was collected at 4, 6, 9, and 12 days postinfection, and cytokines and chemokines were
measured by Bio-Plex array. Data represent the mean standard deviation for 5 to 11 mice per group. Statistical significance was determined using the Mann-Whitney test, and P
values were obtained after comparison to WT mice infected in parallel.
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Irf3/ Irf5/ Irf7/ TKO mice were similar to those reported
for Ifnar/ mice (post hoc comparison with Ifnar/ mice [25],
P
 0.38, 0.16, and 0.14, respectively) but greater those observed
in Irf3/ Irf7/DKOmice (P
 0.005, 0.013, and 0.003, respec-
tively).
In contrast to the case for Irf3/ Irf5/ Irf7/ TKO mice,
infectious OROVwas detected only in the brain and spinal cord at
9 days or after in Irf5/ mice (Fig. 2G and H) and was not de-
tected in any of the peripheral organs. At day 12, 9 of 13 (69%)
Irf5/ mice had measurable OROV in the brain or spinal cord,
with high titers recovered (5.1 104 to 4.8 107 FFU/g and 5
105 to 8  107 FFU/g, respectively). In comparison, only 1 of 11
Irf3/ Irf7/ DKO mice had measurable infectious OROV in
the brain and spinal cord at days 9 after inoculation, and no virus
wasmeasured at day 12 (Fig. 2G andH). These results suggest that
IRF-5, rather than IRF-3 or IRF-7, preferentially regulates a stage
of OROV control which is essential for restricting dissemination
to or infection within the CNS.
To evaluate further whether IRF-5 limits OROV earlier in the
course of infection, we evaluated the viral burden levels by a more
sensitive quantitative reverse transcriptase PCR (qRT-PCR) assay.
At day 6 after infection, higher levels of OROV RNA were ob-
served in the sera (188-fold, P 
 0.0001), livers (248-fold, P 

0.02), spleens (55-fold, P 
 0.03), and kidneys (204-fold, P 

0.0001) of Irf5/mice than in those of WT mice (Fig. 2I to O).
Blood chemistry analysis reveals transient liver damage in
OROV-infected Irf5/mice. Our prior study showed that defi-
ciencies of type I IFN signaling (Ifnar/), RIG-I-like receptor
signaling (Mavs/), or downstream transcription factors
(Irf3/ and Irf7/) resulted in uncontrolled replication of
OROV in peripheral organs that was associated with extensive
liver damage (25). To assess whether visceral organ damage oc-
curred in Irf5/ mice after OROV infection, we measured the
levels of alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), glucose (GLU), blood urea nitrogen (BUN), creati-
nine (CRE), alkaline phosphatase (ALKP), and creatine kinase
(CK) in the sera of WT, Irf5/, and Irf3/ Irf5/ Irf7/ TKO
mice. Although BUN, ALKP, and CK levels were similar in in-
fected WT and KO animals (Table 1), higher levels of ALT (1,243
U/liter and 969 U/liter) and AST (1,097 U/liter and 965U/liter)
and lower levels of GLU (262mg/dl and 106mg/dl) were detected
in the sera of Irf3/ Irf5/ Irf7/TKOand Irf5/mice at days
4 and 6 after OROV infection, respectively, than in WT animals
(Fig. 3A to C). In contrast to that observed in Irf3/ Irf5/
Irf7/ TKO and Ifnar/ mice (25), the lethality observed in
Irf5/mice was not associated with massive hepatic injury, since
the levels of ALT, AST, and GLU normalized at later time points,
even in the subset of animals that became ill.
Analysis of serum cytokine levels in Irf5/ mice infected
with OROV. IRF-5 has been reported to regulate serum cytokine
accumulation in the context of arthropod-borne virus infections
in vivo (11). We measured the levels of 23 cytokines and chemo-
kines in sera from WT, Irf5/, and Irf3/ Irf5/ Irf7/ TKO
mice on days 4, 6, 9, and 12 after OROV infection. Similar to
published data (25) for Ifnar/ and Irf3/ Irf7/ DKO mice,
we did not observe elevated levels of vasoactive (e.g., TNF-) or
FIG4 Serum cytokine levels inOROV-infected Irf5/ and Irf3/ Irf5/ Irf7/TKOmice. (A to E)WT, Irf5/, and Irf3/ Irf5/ Irf7/TKOmicewere
infected with 106 FFU of OROV. Four, 6, 9, or 12 days later, serumwas collected and the levels of the indicated cytokines were determined. Data points represent
individual mice, and the bars indicate the mean values standard deviations (SD). A blue cross indicates that all OROV-infected Irf3/ Irf5/ Irf7/ TKO
animals were dead at the indicated time point. The data correspond to 4 to 13 mice per each group from two independent experiments. Asterisks indicate
statistical significance compared to serum fromOROV-infectedWTmice as judged by the Mann-Whitney test (***, P 0.001; ****, P 0.0001). Dashed lines
represent themean values from threemock-infected animals. (F)WT and Irf5/micewere infectedwithOROV, and 1, 2, and 3 days later, the type I IFN activity
in serum was measured by an EMCV inhibition bioassay. Data are shown as the means for 5 to 10 mice per group from two independent experiments, and
asterisks represent statistical significance as determined by 2-way ANOVA (****, P 0.0001).
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inflammasome-generated (e.g., IL-1) cytokines in the OROV-
infected Irf3/ Irf5/ Irf7/ TKO or Irf5/ mice (Table 2).
However, the levels of other proinflammatory cytokines and
chemokines (e.g., IL-6, IL-12p40, G-CSF, KC, and MIP-1) were
increased at day 4 after OROV infection in Irf3/ Irf5/ Irf7/
TKO mice (Fig. 4A to E). Because the levels of all analyzed cyto-
kines were similar in Irf5/ andWTmice after OROV infection,
the mild liver damage observed in Irf5/ mice is unlikely to be
due to a generalized cytokine storm.
To assess whether a deficiency of IRF-5 affected systemic type I
IFN responses, we measured type I IFN antiviral activity in sera
from WT and Irf5/ animals at days 1, 2, and 3 after OROV
infection using an established bioassay (28). At day 1 after OROV
infection, Irf5/ and WT mice both had slightly higher levels of
type I IFN than mock-infected mice (Fig. 4F). Type I IFN activity
in serumwaned inWT animals after 2 days of infection. However,
significant increases in type I IFN were apparent (44-fold, P 
0.0001) at day 3 after OROV injection in Irf5/mice. These high
levels of type I IFN in Irf5/ mice suggest an ongoing OROV
infection and a relatively intact systemic IFN response.
OROV-induced disease in Irf3/ Irf5/ Irf7/ TKOmice
is associated with viral replication and hepatocyte death. To
characterize the basis of the liver injury observed in Irf3/
Irf5/ Irf7/ TKO infected mice, we performed pathological
analysis on hepatic tissue isolated from WT, Irf5/, and Irf3/
Irf5/ Irf7/ TKO mice at day 4 after OROV infection. While
hematoxylin-and-eosin staining revealed areas of edema and focal
cellular necrosis in liver sections of Irf3/ Irf5/ Irf7/ TKO
mice, these changes were not apparent in samples from WT and
Irf5/ infected mice (Fig. 5A). The liver damage in Irf3/
Irf5/ Irf7/ TKOmice was associated with greater numbers of
terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling (TUNEL)-positive (Fig. 5B) andOROVantigen-
positive (Fig. 5C) hepatocytes at day 4 after infection. In compar-
ison, a smaller number of TUNEL- and OROV-positive cells were
observed in the livers of Irf5/mice, and none were detected in
WT mice.
Effect of IRF-5 on OROV-induced neuropathology. Given
the presence ofOROV in the brain and spinal cord of some Irf5/
mice (Fig. 2), we performed histological analysis on brain sections
from WT and Irf5/ mice to define why some animals suc-
cumbed to infection. TUNEL-positive cells were detected in dif-
ferent regions of the brain, including the cerebral cortex, hip-
pocampus, midbrain, and cerebellum, from OROV-infected
Irf5/mice (Fig. 6A toD).Moreover, abundant staining for viral
antigen was detected in several regions of the brain of OROV-
infected Irf5/mice but not in infectedWTor uninfected Irf5/
mice (Fig. 7A to D). In agreement with a published study that
reported costaining for viral antigen with a neuron marker
(NeuN) in newbornmice infectedwithOROV (31), themorphol-
ogy of viral antigen-positive cells in Irf5/mice was consistent
with neurons being targeted for infection (Fig. 7B and C), partic-
ularly in the hippocampus.
WT and Irf5/mice are equally vulnerable to OROV infec-
tionwhen inoculatedbyan intracranial route.Todefinewhether
the enhanced replication of OROV in the brains of Irf5/ mice
was due to an intrinsic inhibitory effect of IRF-5 in the CNS, we
infectedWTand Irf5/micewithOROVby an intracranial route
and monitored morbidity, mortality, and viral burden. We ob-
servednodifferences in survival rates, weight loss, and viral load in
the brains of WT and Irf5/ mice after intracranial infection
(data not shown); 100% of WT and Irf5/ mice succumbed to
FIG 5 Analysis of liver tissue from OROV-infected WT, Irf5/, and Irf3/ Irf5/ Irf7/ TKO mice. (A) Histological (hematoxylin and eosin staining)
analysis of the livers of infectedmice harvested 4 days after OROV infection. (B) Representative images of TUNEL staining of livers of infectedmice taken 4 days
afterOROV infection. (C)Detection ofOROVantigen in livers of infectedmice 4 days after virus infection. Images (magnification,20)were obtained fromone
representative animal from groups of three. Inset images show a higher magnification image (40) and correspond to the region marked by the arrow. Scale
bar
 100 m.
Neuropathogenesis of OROV Is Restricted by IRF-5
January 2016 Volume 90 Number 1 jvi.asm.org 197Journal of Virology
 o
n
 M
ay 2, 2016 by Universidade Estadual de Cam
pinas
http://jvi.asm.org/
D
ow
nloaded from
 
infection by day 7 after intracranial inoculation, with no differ-
ence inmean time to death (data not shown). These results suggest
that IRF-5 does not have a direct antiviral effect against OROV
within the brain but rather is likely important for restricting
spread to the brain.
OROV RNA persists in cells from Irf5/ mice. To begin to
define why a deficiency of IRF-5 resulted in disseminated OROV
infection in the CNS at such a relatively late time point, we tested
tissue samples for virus by qRT-PCR at days 9 and 12 after infec-
tion, which immediately precedes the onset of lethality in Irf5/
mice (Fig. 1). Although samples from all WT mice tested were
negative for OROV RNA at day 12, indicating successful clear-
ance, the sera, livers, spleens, kidneys, lungs, brains, and spinal
cords from more than 50% of Irf5/ mice were positive for
OROV RNA at this late time point (Fig. 8A to G). Analogously, at
day 9 after infection, 3 of 8 (37.5%) and 5 of 8 (62.5%) spinal cord
and brain samples, respectively, from Irf5/ mice were positive
for OROV RNA, whereas none were positive in infectedWTmice
(Fig. 8F and G). The persistence of OROV in different peripheral
organs in Irf5/mice could lead to the selection of an encepha-
litic variant ofOROVwith greater neuroinvasive potential, as seen
with the JC polyomavirus (32, 33). To test this idea, we homoge-
nized brain tissue fromOROV-infected Irf5/mice andused this
to infect WT and Irf5/mice. These isolates were not more vir-
ulent or neuroinvasive than the parental OROV used in this study
in either WT or Irf5/mice (data not shown).
As an alternative hypothesis, we speculated that persistently
infected Irf5/ cells might deliver OROV into the CNS. To de-
termine which cells in Irf5/mice harbored OROV RNA during
late stages of this disease, WT and Irf5/mice were infected with
OROV. As we did not have a fluorescence-activated cell sorter in
our enhanced BSL3 suite, at day 8 after viral infection, different
cell populations were purified from blood by positive selection
with anti-CD19, -CD3, -CD11b, -B220, or -CD11c magnetic
beads (Fig. 9A and B) and tested by qRT-PCR for the presence of
OROV RNA. Populations of CD11c and B220 cells from
Irf5/ mice were frequently (50%) positive for OROV (Fig.
9C), suggesting that these cellsmight transport virus into the brain
directly or propagate virus sufficiently to allow crossing of the
blood-brain barrier (BBB) in the fluid phase.
To evaluate whether a deficiency of IRF-5 could affect the ex-
pression of type I IFN in DCs in vivo, we measured the levels of
IfnbmRNA in CD11c, B220, CD11c, and B220 cell popula-
tions from WT and Irf5/ mice obtained 8 days after OROV
infection. The levels of IfnbmRNA were lower in circulating cells
(including CD11c cells [18-fold, P 0.05] and B220 cells [23-
fold,P 0.05]) from Irf5/ infectedmice than in those fromWT
mice (Fig. 9D) despite the increased levels of OROV infection.
These data suggest that IRF-5 signaling is essential to induce op-
timal type I IFN responses in peripheral blood mononuclear cells
(PBMCs) after OROV infection.
OROV replication is enhanced and the production of type I
FIG 6 Dying cells are present in the brains of OROV-infected Irf5/mice. TUNEL analysis of the cerebral cortex (A), cerebellum (B), hippocampus (C), and
midbrain (D) frommice harvested 12 days after OROV infection is shown. Representative images (magnification,10) were obtained from three mice of each
group. Inset images show a magnified image and correspond to the region marked by the arrow. Scale bars
 100 m.
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IFN is diminished in DCs from Irf5/ mice. As DCs from
Irf5/ mice produced less Ifnb and appeared to support greater
OROV replication in blood, to corroborate these findings, we
evaluated viral growth kinetics and type I IFN mRNA expression
in bone marrow-derived DCs and M from WT, Irf5/, and
Irf3/ Irf5/ Irf7/ TKO mice. In DCs, OROV infection was
greater in cells derived from Irf3/ Irf5/ Irf7/ TKO cells
(10,000-fold [P  0.01]) at 36 to 60 h than in WT cells, which
failed to support productive infection (Fig. 10A). Higher levels
(130- to 1,750-fold higher, P 0.05) of viral replication also were
observed in DCs from Irf5/mice than in those fromWTmice.
In comparison, in M, productive OROV infection was detected
only in cells derived from Irf3/ Irf5/ Irf7/ TKO and not
WT or Irf5/mice (Fig. 10B). Thus, in cell culture a deficiency of
IRF5 resulted in enhanced OROV infection specifically in DCs,
which supports our ex vivo and in vivo findings of elevated OROV
RNA in Irf5/CD11c cells and sustained viremia and spread to
the CNS in Irf5/mice. Moreover, and despite the higher levels
of OROV infection, lower levels of Ifna and Ifnb mRNA were
observed in bone marrow-derived DCs from Irf5/mice than in
those fromWTmice (Fig. 10C andD). A lesser impact of IRF-5 on
Ifna but not IfnbmRNA induction was observed in bonemarrow-
derived M after OROV infection (Fig. 10E and F).
Effect of IRF-5 on antibody responses after OROV infection.
WTmice efficiently cleared OROV infection from all tissue com-
partments, whereas infection persisted in mice lacking IRF-5.
Given prior studies demonstrating skewed antibody isotype re-
sponses, deficient B cell maturation, and low levels of antigen-
specific memory B cells in Irf5/ mice (9, 11, 34), we hypothe-
sized that IRF-5might be required for optimal adaptive immunity
against OROV. To evaluate the role of IRF-5 in the humoral re-
sponse against OROV, we determined the titers of neutralizing
antibody at days 8 and 12 after infection in WT and Irf5/mice
(Fig. 11A and B). Irf5/mice had only slightly lower neutralizing
titers at days 8 (2.1-fold, P  0.005) and 12 (1.5-fold, P  0.01)
than WT mice. To assess the importance of IRF-5 in the B cell
response against OROV, we generated bone marrow chimeric
mice that differed only in the expression of IRF-5 in B cells. We
FIG 7 OROV detection in the brains of Irf5/mice after 12 days of infection. Immunohistochemical analysis after staining with polyclonal anti-OROV ascites
fluid of the cerebral cortex (A), cerebellum (B), hippocampus (C) and midbrain (D) from uninfected, WT, and Irf5/ infected mice. Images are derived from
one representative animal obtained from a group of three animals. All sections were taken at 12 days of infection and the images were obtained using a
magnification of20. A higher resolution of infected cells is shown in the inset with a higher magnification image (40), corresponding to the region marked
by the arrow. Scale bars
 100 m.
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adoptively transferred WTMT (lacking all mature B cells) or
Irf5/MT bone marrow cells from CD45.2 mice into suble-
thally irradiated 4-week-old WT CD45.1 recipient mice. Eight
weeks later, the reconstitution of donor immune cell populations
in blood was confirmed by flow cytometry and all recipient ani-
mals were infected with 106 FFU of OROV (data not shown).
However, no difference in weight loss or viral load in the brain at
day 12 was observed between the two groups (data not shown).
Thus, we did not observe a B cell-intrinsic role for IRF-5 in pro-
tection against OROV infection in the CNS.
IRF-5 restricts the neuropathogenesis of other orthobunya-
virus. To evaluate whether IRF-5 also restricts infection of other
orthobunyaviruses in vivo, we infected 8-week-old WT, Irf5/,
Irf3/ Irf7/DKO, and Irf3/ Irf5/ Irf7/ TKOmice with
LACV (105 FFU), a related encephalitic orthobunyavirus. Similar
to our resultswithOROV, rapid lethalitywas observed after LACV
infection of Irf3/ Irf7/DKOand Irf3/ Irf5/ Irf7/TKO
mice (Fig. 12A). Remarkably, Irf5/ mice infected with LACV
failed to gain weight, showed clinical signs of neuroinvasive dis-
ease, and succumbed to infection after day 9 (Fig. 12B to E). Con-
sistent with this, higher titers of LACVwere observed in the brains
and spinal cords (290- to 50,000-fold, P 0.05) of Irf5/mice at
days 8 and 12 after infection than in those of WT mice (Fig. 12F
and G). These results establish that IRF-5 restricts infection and
neuropathogenesis of two different orthobunyaviruses.
DISCUSSION
Our study describes an innate immune mechanism for restricting
neuroinvasion of two different orthobunyaviruses that cause
meningitis and encephalitis. IRF-5, a transcription factor that is
activated after recognition of pathogen-associated molecular pat-
terns (4), orchestrates a host response that controls bunyavirus
neuroinvasion in infectedmice. Irf5/mice died beginning at 12
days after OROV infection, a time when high levels of infectious
virus were detected exclusively in the brain and spinal cord. The
relative importance of IRF-5 to the antiviral response against
OROV is highlighted by comparisons with Irf3/ or Irf7/ sin-
gle-KO mice, which sustained no or substantially lower levels of
mortality after infection (25). Moreover, significant levels of
OROV infection were observed in the CNS of Irf5/ but not
Irf3/ Irf7/DKOmice. Thus, IRF-5, rather than IRF-3 and/or
IRF-7, regulates a stage in the control of OROV pathogenesis that
prevents dissemination to the brain and spinal cord.
Apart from its effect on neuroinvasion, IRF-5 also restricted
OROVreplication in the liver, spleen, and blood at earlier stages of
infection. The evidence for this comes from studies with Irf5/
mice and also by comparing OROV pathogenesis between Irf3/
Irf7/ DKO and Irf3/ Irf5/ Irf7/ TKO mice. The
Irf3/ Irf5/ Irf7/ TKO mice were highly vulnerable to
OROV infection and succumbed with kinetics similar to those for
Ifnar/mice (25), whereas DKO mice were less susceptible. Ac-
cordingly, the levels of infectious virus in the liver, spleen, and
blood were higher in Irf3/ Irf5/ Irf7/ TKO mice than n
Irf3/ Irf7/DKOmice (25). Consistent with a role for IRF-5 in
restrictingOROV replication in peripheral organs, higher levels of
viral RNAwere detected in the serum, liver, spleen, and kidneys of
Irf5/ than in WT mice at day 6 after infection.
OROV infection of 5- to 6-week-old Irf5/ mice caused en-
cephalitis after subcutaneous inoculation. The morphology of the
antigen-positive cells observed in the brains of Irf5/ mice was
consistent with neurons as a primary target of infection. Previ-
ously, OROV was reported to cause encephalitis in newborn in-
bred WT mice and was associated with paralysis and mortality
(31). OROVwas recovered from the brain and spinal cord at days
4 and 5 after infection of newborns and was detected almost ex-
clusively in neurons (31). OROV also induced meningoencepha-
litis in adult golden hamsters, with viral antigen present in brain
cells that morphologically resembled neurons (35). We also ob-
FIG 8 OROVRNA is detected in Irf5/mice at later time points. The viral burden after OROV infection ofWT and Irf5/mice was determined by qRT-PCR
in samples from serum (A), liver (B), spleen (C), kidney (D), lung (E), brain (F), and spinal cord (G). Data points represent individualmice. Bars indicatemedian
values and were obtained from 6 to 13mice per time point. Dashed lines represent the limit of sensitivity of the assay. Asterisks indicate statistical significance as
judged by the Mann-Whitney test (*, P 0.05; **, P 0.01; ****, P 0.0001).
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FIG 9 OROV induces less type I IFN production in circulating DC populations from Irf5/mice at late time points after OROV infection. (A) Cell isolation
scheme. CD3, CD19, CD11b, CD11c, and B220 cells were purified at day 8 after OROV infection from WT and Irf5/mice by positive selection using
antibody-coatedmagnetic beads. CD19 cells were purified from the whole blood of 6WT and Irf5/mice, and the CD3 and CD11b cells were sequentially
purified using the flowthrough fromCD19 andCD3 cells, respectively. As CD19-, CD3-, andCD11b-negative cells had detectableOROVRNAonly in Irf5/
mice, CD11c cells and B220 cells subsequently were purified directly fromwhole blood pooled of 5WT and Irf5/mice. (B) Flow cytometry of the different
cell populations purified by positive selection, showing the forward scatter (FSC) versus staining with the specific antibody conjugated with fluorescein
isothiocyanate (FITC). The percentage of specific positive cells is shown in the gate. (C)Number of copies ofOROVRNAper cell in the different cells populations
as determined by qRT-PCR after normalization toGapdh. Each symbol indicates results from pools of mice, following the scheme described above. (D) Relative
expression levels of IfnbmRNA as determined by qRT-PCR. Gene expression was normalized toGapdhmRNA and is shown as the fold increase compared to the
cells from mock-infected mice on a log2 scale. The basal level of Ifnb mRNA was barely detectable and was similar in cells from WT and Irf5
/ mice. Data
represent the averages from three independent experiments performed in triplicate and are expressed as the means  SD, and asterisks indicate statistical
significance (*, P 0.05) as determined by 2-way ANOVA. The dotted line represents the limit of detection.
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served that40%of 8-week-old Irf5/mice infectedwith LACV
developed signs of neurological involvement, including dyskine-
sia and paresis. In all symptomatic animals, we recovered infec-
tious LACV.
How does IRF-5 control bunyavirus neuropathogenesis? We
initially hypothesized that IRF-5 could affect viral replication di-
rectly in neurons. However, and as seen with the unrelated en-
cephalitic flavivirus WNV (11), no major differences in viral bur-
den in the brainwere observed betweenWTand Irf5/mice after
intracranial inoculation of OROV. This result suggests that the
protective effect of IRF-5 against OROV or LACV is not due to a
CNS-intrinsic antiviralmechanism. Given these findings, we eval-
uated whether a deficiency of IRF-5 affected OROV replication in
circulating PBMCs, which could contribute to viremia or possibly
crossing of virus into the brain via a “Trojan horse” mechanism
(36). Analysis of viral RNA levels obtained from purified PBMC
subsets of OROV-infected mice revealed that B220 and CD11c
cell subsets from Irf5/ mice supported higher levels of OROV
infection. However, these OROV-expressing cells were not suffi-
cient to infect the CNS, as adoptive transfer of PBMCs or DCs
fromOROV-infected Irf5/mice did not induce disease in naive
WT or Irf5/mice (data not shown). This result was not entirely
unexpected, since infection of leukocytes alone does not disrupt
the BBB in other viral models (37, 38). Although further experi-
ments are warranted, IRF-5 could regulate expression of mole-
cules that sustain the BBB integrity. An absence of IRF-5 then
would result in increased viremia, infection of PBMCs, and BBB
permeability, all of which together could promote virus neuroin-
vasion.
Because both B220 and CD11c purified cells were positive
FIG 10 OROV replicates in culturedDCs but notM from Irf5/mice. (A and B) Kinetics of OROV replication in bonemarrow-derivedDCs (A) andM (B)
fromWT, Irf5/, and Irf3/ Irf5/ Irf7/TKOmice after infection at anMOI of 0.001. The data represent themean SDof three independent experiments
performed in triplicate. All KO cell groups were compared to the WT by a two-way ANOVA, and asterisks indicate statistical significance (*, P 0.05; **, P
0.01; ***, P  0.001). The dotted line represents the limit of detection of the assay. (C to F) Kinetics of Ifna (C and E) and Ifnb (D and F) expression in bone
marrow-derived DCs (C and D) andM (E and F) fromWT, Irf5/, and Irf3/ Irf5/ Irf7/ TKOmice after infection with OROV using anMOI of 0.001.
The relative levels of Ifna and IfnbmRNAs were determined by qRT-PCR after normalization to GapdhmRNA and are displayed as CT values compared to
the mock-infected cells on a log2 scale. The basal levels of Ifna and IfnbmRNAs were barely detectable and were similar in cells fromWT and Irf5
/mice. Data
represent the averages from three independent experiments performed in triplicate and are expressed as the means  SD. The asterisks indicate statistical
significance by two-way ANOVA (*, P 0.05; **, P 0.01), and the dotted line represents the limit of detection.
FIG 11 Effect of IRF-5 on the early antibody response in OROV-infected mice.
The presence of neutralizing antibody in the sera fromWT and Irf5/mice at 8
(A) and 12 (B) days afterOROV infection as judgedby a plaque reduction assay in
Vero cells after incubationwith 100 PFUofOROVand log2 dilutions of the tested
serum is shown. Data represent the means for 8 mice per group from two inde-
pendent experiments performed in duplicate. All error bars represent the SD. The
PRNT50 represents the dilution that showed 50% reduction in plaque formation
in comparison with a control without serum after linear regression analysis.
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forOROVRNAat later time points (day 8) after viral infection, we
speculated that the plasmacytoid DC (pDC) subset might be a
primary target. IRF-5 regulates both IL-6 and IFN- gene expres-
sion in pDCs (12), and these cells are a primary source of type I
IFNs and proinflammatory cytokines after virus infection (17,
39). Although a definitive identification of pDCs as the key DC
subset regulating CNS infection of OROV and LACV in Irf5/
mice warrants further study, we observed lower expression levels
of Ifna and IfnbmRNAs after OROV infection in DCs in vivo and
in cell culture. Thus, infection of specific subsets ofDCs, including
possibly pDCs, could modulate the production of antiviral cyto-
kines and control of viral infection in blood. For bunyaviruses,
this process appears to require an optimal IRF-5 signaling path-
way, as in its absence viral persistence in serum occurs, and this is
associatedwith neuroinvasion. This process appears to be cell type
dependent, as in M an absence of IRF-5 did not impact OROV
infection or IFN- induction, and we observed no decrease in
overall type I IFN levels in the sera of Irf5/mice at day 1, 2, or 3
after infection. Rather, type I IFN levels were higher in the sera of
Irf5/ mice at day 3 after infection; although the mechanism
remains uncertain, this phenotype could reflect greater levels of
OROV replication in another cell type or tissue.
IRF-5 is essential to B cell differentiation and modulates the
expression of the plasma B cell maturation factor Blimp-1 (9).
Irf5/mice have fewer T cells, B cells, NK cells, M, and DCs in
the draining lymph nodes at day 2 after WNV infection than WT
mice, and these mice have defects in generating an optimal acute
and memory B cell response (11). Although Irf5/ mice had
slightly lower levels of neutralizing antibody against OROV at day
7 after infection, it is unclear if these small differences contributed
to neuroinvasion. Bone marrow chimera reconstitution studies
failed to show a protective role for IRF-5 in the B cell compart-
ment.
In summary, our study shows that IRF-5 is a key component of
the immune response against orthobunyaviruses and contributes
to restricting neuroinvasion. This phenotype was associated with
the defects in the control of replication and clearance of virus from
circulating PBMCs. The persistent circulation of virus in the blood
of Irf5/mice correlated with neuroinvasion and viral burden in
the brain and spinal cord. Future studies with conditionally tar-
geted IRF-5-deficent mice are planned to define the role of IRF-5
in specific cell types on neuroinvasion. The animal model de-
scribed here may be useful for understanding the basic biology of
the encephalitis induced byOROV, as well as for testing candidate
therapeutics and vaccines. Finally, the antiviral activity of IRF-5
against different families of viruses capable of causing lethal CNS
infection could explain the selection and perpetuation of gain-of-
function IRF5 alleles in the human population.
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FIG 12 IRF-5 controls the neuropathogenesis of infection by LACV, a related orthobunyavirus. (A) Survival analysis of 8-week-old mice after inoculation with
105 FFU (n
 23 forWT, n
 17 for Irf5/, n
 16 for Irf3/ Irf7/DKO, and n
 5 for Irf3/ Irf5/ Irf7/TKO). Asterisks indicate differences that were
statistically significant with a comparison toWTmice by the log rank test (*, P 0.05; ****, P 0.0001). (B to D)Weight loss analysis of 8-week-old mice after
inoculation with 105 FFU of LACV by footpad inoculation in the same mice. Data are pooled from at least two independent experiments. Weight loss was
compared by 2-way ANOVA. Asterisks indicate differences that were statistically significant with a comparison to WT animals with the same viral dose (*, P
0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001). (F and G) The viral burden after LACV infection of WT or Irf5/mice was determined by qRT-PCR in
samples from brain (F) and spinal cord (G). Data points represent individual mice. Bars indicate median values and were obtained from 8 to 12 mice per time
point. Dashed lines represent the limit of sensitivity of the assay. Asterisks indicate statistical significance as judged by theMann-Whitney test (*, P 0.05; **, P
 0.01).
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